Japanese Patent Grants For IMP321 In Cancer
Filed with ASX · · 2 pages · English
Earlier from Immutep
- Appendix 4C - quarterly March 2016
- Proposed Acquisition of Immutep
- First patient dosed in AIPAC
- US patent granted for IMP731 antibody
- Prima initiates Phase I melanoma study in Australia
Later from Immutep
- PRR Enters Agreement with Sydys to Advance CVac Program
- Prima BioMed Files U.S Shelf Registration Statement
- First Data From Phase IIb Clinical Trial of Imp321
- PRR Collaborates In New Clinical Trial For Imp321
- European Patent Grants for IMP731 Antibody
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep